PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Arthur Radley who wrote (46)	4/14/1998 9:28:00 AM
From: Brander	Read Replies (3) of 626

TexasDude The rare, but potentially fatal, side effects of Clozaril are why this drug is losing market share. It works better than the traditional antipsychotics on both positive and negative symptoms of schizophrenia, but the weekly blood monitoring (monitoring for potential agranulocytosis) make this drug troublesome for the patint to take and very expensive. This is why Risperdal and Zyprexa are doing so well. Seroquel might also pick up. In addition to being much, much safer, Risperdal and Zyprexa probably also improve the negative symptoms more than Clozaril. Novartis is smart to partner with Titan. If they want to stay in the antipsychotic medication market, they need a replacement for Clozaril. It is fading fast. Brad

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next